Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 4.7% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares traded up 4.7% during trading on Tuesday. The stock traded as high as $4.00 and last traded at $3.8750. 10,114,293 shares were traded during trading, a decline of 45% from the average daily volume of 18,239,877 shares. The stock had previously closed at $3.70.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on RXRX shares. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Trading Down 1.6%

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -3.89 and a beta of 1.07. The business has a fifty day moving average price of $3.39 and a 200 day moving average price of $3.34.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter in the previous year, the business posted ($0.41) EPS. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current fiscal year.

Insider Activity

In related news, Director Blake Borgeson sold 40,000 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 122,408 shares of company stock worth $434,976. Insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. MCF Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 2nd quarter worth approximately $27,000. WINTON GROUP Ltd boosted its stake in shares of Recursion Pharmaceuticals by 85.2% in the 2nd quarter. WINTON GROUP Ltd now owns 192,800 shares of the company’s stock valued at $708,000 after purchasing an additional 88,700 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Recursion Pharmaceuticals by 85.8% during the 2nd quarter. Squarepoint Ops LLC now owns 98,426 shares of the company’s stock worth $361,000 after acquiring an additional 45,438 shares during the period. Arizona State Retirement System increased its holdings in Recursion Pharmaceuticals by 6.5% in the second quarter. Arizona State Retirement System now owns 129,619 shares of the company’s stock valued at $476,000 after purchasing an additional 7,913 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at approximately $189,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.